Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
Philippe Gautret, Jean-Christophe Lagier, Philippe Parola, Van Thuan Hoang, Line Meddeb, Jacques Sevestre, Morgane Mailhe, Barbara Doudier, Camille Aubry, Sophie Amrane, Piseth Seng, Marie Hocquart, Carole Eldin, Julie Finance, Vera Esteves Vieira, Hervé Tissot Tissot-Dupont, Stéphane Honoré, Andreas Stein, Matthieu Million, Philippe Colson, Bernard La Scola, Véronique Veit, Alexis Jacquier, Jean-Claude Deharo, Michel Drancourt, Pierre Edouard Fournier, Jean-Marc Rolain, Philippe Brouqui, Didier Raoult, Philippe Gautret, Jean-Christophe Lagier, Philippe Parola, Van Thuan Hoang, Line Meddeb, Jacques Sevestre, Morgane Mailhe, Barbara Doudier, Camille Aubry, Sophie Amrane, Piseth Seng, Marie Hocquart, Carole Eldin, Julie Finance, Vera Esteves Vieira, Hervé Tissot Tissot-Dupont, Stéphane Honoré, Andreas Stein, Matthieu Million, Philippe Colson, Bernard La Scola, Véronique Veit, Alexis Jacquier, Jean-Claude Deharo, Michel Drancourt, Pierre Edouard Fournier, Jean-Marc Rolain, Philippe Brouqui, Didier Raoult
Abstract
Background: We need an effective treatment to cure COVID-19 patients and to decrease virus carriage duration.
Methods: We conducted an uncontrolled, non-comparative, observational study in a cohort of 80 relatively mildly infected inpatients treated with a combination of hydroxychloroquine and azithromycin over a period of at least three days, with three main measurements: clinical outcome, contagiousness as assessed by PCR and culture, and length of stay in infectious disease unit (IDU).
Results: All patients improved clinically except one 86 year-old patient who died, and one 74 year-old patient still in intensive care. A rapid fall of nasopharyngeal viral load was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% of patients at Day5. Consequently patients were able to be rapidly discharged from IDU with a mean length of stay of five days.
Conclusion: We believe there is urgency to evaluate the effectiveness of this potentially-life saving therapeutic strategy at a larger scale, both to treat and cure patients at an early stage before irreversible severe respiratory complications take hold and to decrease duration of carriage and avoid the spread of the disease. Furthermore, the cost of treatment is negligible.
Keywords: Azithromycin; COVID-19; Culture; Hydroxychloroquine; PCR; SARS-CoV-2.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Figures
Fig. 2
SARS-CoV-2 culture from nasopharyngeal samples…
Fig. 2
SARS-CoV-2 culture from nasopharyngeal samples overtime. Black bars: number of patients with available…
References
- Lai C.C., Shih T.P., Ko W.C., Tang H.J., Hsueh P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55
- Zhu N., Zhang D., Wang W., Li X., Yang B., Song J. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
- WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. 2020.
- Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. J Am Med Assoc. 2020
- Coronavirus COVID-19 global cases by the center for systems science and engineering (CSSE) at johns Hopkins University (JHU) accessed on March, 26th, 2020 from.
- Colson P., Rolain J.M., Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020
- Colson P., Rolain J.M., Lagier J.C., Brouqui P., Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020
- Yao X., Ye F., Zhang M., Cui C., Huang B., Niu P. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clin Infect Dis. 2020
- Liu J., Cao R., Xu M., Wang X., Zhang H., Hu H. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.
- Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271.
- Nabirothckin S., Peluffo A.E., Bouaziz J., Cohen D. Focusing on the unfolded protein response and autophagy related pathways to reposition common approved drugs against COVID-19. Preprints. 2020 doi: 10.20944/preprints202003.0302.v1.
- Gao J., Tian Z., Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020
- Chinese Clinical Trial Registry
- Zhou D., Dai S.M., Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020
- Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jiehe He Huxi Zazhi. 2020;43:185–188.
- Gautret P., Lagier J.C., Parola P., Hoang V.T., Meddeb L., Mailhe M. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020
- Chen J., Liu D., Liu L., Liu P., Xu Q., Xia L. J of Zjeijang University; 2020. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)
- Chen Z., Hu J., Zhang Zo, Jiang S., Han S., Yan D. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. 2020 doi: 10.1101/2020.03.22.20040758.
- Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020
- Liao X., Wang B., Kang Y. Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units-the experience in Sichuan Province, China. Intensive Care Med. 2020;46:357–360.
- Corman V.M., Landt O., Kaiser M., Molenkamp R., Meijer A., Chu D.K.W. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020:25.
- Amrane S., Tissot-Dupont H., Doudier B., Eldin C., Hocquart M., Mailhe M. Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infections diseases referral hospital in Marseille, France, -January 31st to March 1st, 2020: a respiratory virus snapshot. Trav Med Infect Dis. 2020 in press.
- To K.K., Tsang O.T., Leung W.S., Tam A.R., Wu T.C., Lung D.C. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet. 2020 Published on line March 23,2020.
- Liu Y., Yan L.M., Wan L., Xiang T.X., Le A., Liu J.M. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020
- Chang Mo G., Yuan X., Tao Y., Peng X., Wang F. Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection. Am J Respir Crit Care Med. 2020
- Mitja O., Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Health. 2020
- Chatre C., Roubille F., Vernhet H., Jorgensen C., Pers Y.M. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf. 2018;41:919–931.
- Hicks L.A., Taylor T.H., Jr., Hunkler R.J. U.S. outpatient antibiotic prescribing, 2010. N Engl J Med. 2013;368:1461–1462.
Source: PubMed